Newdel Biotech
Latest round
- Series A
Last raised
- Mar 2024
Total raised
- Undisclosed
Investors
- 2
About Newdel Biotech
, trading as Newdel Biotech, is a biotechnology company that focuses on the R&D and production of new drugs. It is incubated by Guangdong Small Molecule Drug Innovation Center.0 technology platform in August 2021 and initiated preclinical studies for its original new drug, ND-003, in April 2022. Newdel Biotech engages in the R&D of small molecule drugs, focusing on antitumor drugs. The company also provides immune checkpoint inhibitors and anti-infective and metabolic diseases. Those candidate drugs are acquired by DNA Encoded Library (DEL) technology, which is a high throughput live-cell screening technology and can screen membrane proteins that are difficult to purify. It also built a 0-1 drug discovery technology platform (DEL+X) and has a compound library of more than 100 billion real molecules. The company generates revenue by developing small molecule innovative drugs.
Who invested in Newdel Biotech
2 investors across 2 rounds
See all investors in Newdel Biotech
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Newdel Biotech
Who invested in Newdel Biotech?
Newdel Biotech has 2 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Newdel Biotech raised?
Newdel Biotech has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Newdel Biotech last raise money?
Newdel Biotech's most recent round on record is a Series A, in Mar 2024.
What does Newdel Biotech do?
, trading as Newdel Biotech, is a biotechnology company that focuses on the R&D and production of new drugs.
Where is Newdel Biotech headquartered?
Newdel Biotech is headquartered in Shenzhen, China.
Which VCs invest in companies like Newdel Biotech?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Newdel Biotech's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Newdel Biotech? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.